Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Inclusion Criteria: * A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted * Current or former cigarette smokers Exclusion Criteria: * Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit * Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1 * Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness * History or presence of asthma verified from medical records * Chronic use of oxygen therapy greater than or equal to 15 hours per day * Patient with uncontrolled infection due to HIV and/or active hepatitis * Patients with a history of hypersensitivity reaction to inhaled anticholinergics * Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.